Personalized Oncology in Interventional Radiology

被引：26

作者：

Abi-Jaoudeh, Nadine ^{[1
]}

Duffy, Austin G. ^{[2
]}

Greten, Tim F. ^{[2
]}

Kohn, Elise C. ^{[2
]}

Clark, Timothy W. I. ^{[3
]}

Wood, Bradford J. ^{[1
]}

机构：

[1] NIH, Bethesda, MD 20892 USA

[2] NIH, Med Oncol Branch, Bethesda, MD 20892 USA

[3] Penn Presbyterian Med Ctr, Sect Intervent Radiol, Philadelphia, PA USA

来源：

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 2013年 / 24卷 / 08期

基金：

美国国家卫生研究院;

关键词：

METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; 1ST-LINE TREATMENT; TARGETED THERAPIES; PLUS IRINOTECAN; CLINICAL-TRIALS; BREAST-CANCER; BEVACIZUMAB; BIOMARKERS;

D O I：

10.1016/j.jvir.2013.04.019

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

100231 [临床病理学]; 100902 [航空航天医学];

摘要：

As personalized medicine-becomes more applicable to oncologic practice, image-guided biopsies will be integral for enabling predictive and pharmacodynamic molecular pathology. Interventional radiology has a key role in defining patient-specific Management. Advances in diagnostic techniques, genomics, and proteomics enable a window into subcellular mechanisms driving hyperproliferation, metastatic capabilities, and tumor angiogenesis. A new era of personalized medicine has evolved whereby clinical decisions are adjusted according to a patient's molecular profile. Several mutations and key markets already have been introduced into standard oncologic practice. A broader understanding of personalized oncology will help interventionalists play a greater role in therapy selection and discovery.

引用

页码：1083 / 1092

页数：10

共 52 条

[1]

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].

Adams, Richard A. ;

Meade, Angela M. ;

Seymour, Matthew T. ;

Wilson, Richard H. ;

Madi, Ayman ;

Fisher, David ;

Kenny, Sarah L. ;

Kay, Edward ;

Hodgkinson, Elizabeth ;

Pope, Malcolm ;

Rogers, Penny ;

Wasan, Harpreet ;

Falk, Stephen ;

Gollins, Simon ;

Hickish, Tamas ;

Bessell, Eric M. ;

Propper, David ;

Kennedy, M. John ;

Kaplan, Richard ;

Maughan, Timothy S. .

LANCET ONCOLOGY, 2011, 12 (07) :642-653

[2]

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 [J].

Annunziata, Christina M. ;

Walker, Amanda J. ;

Minasian, Lori ;

Yu, Minshu ;

Kotz, Herbert ;

Wood, Bradford J. ;

Calvo, Katherine ;

Choyke, Peter ;

Kimm, Daniel ;

Steinberg, Seth M. ;

Kohn, Elise C. .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :664-672

[3]

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology [J].

Awada, Ahmad ;

Vandone, Anna M. ;

Aftimos, Philippe .

CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) :297-304

[4]

Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond [J].

Ballestrero, A. ;

Garuti, A. ;

Cirmena, G. ;

Rocco, I. ;

Palermo, C. ;

Nencioni, A. ;

Scabini, S. ;

Zoppoli, G. ;

Parodi, S. ;

Patrone, F. .

CURRENT CANCER DRUG TARGETS, 2012, 12 (04) :316-328

[5]

Bhakta Shyam, 2009, Clin Cardiol, V32, pE80, DOI 10.1002/clc.20685

[6]

Bilbault P, 2008, AM J EMERG MED, V26, p[971, e5, e7]

[7]

Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials [J].

Black, A. ;

Morris, D. .

CURRENT ONCOLOGY, 2012, 19 :S73-S85

[8]

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

de Braud, F. ;

Schuch, G. ;

Zubel, A. ;

Celik, I. ;

Schlichting, M. ;

Koralewski, P. .

ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546

[9]

Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer [J].

Burris, Howard A., III ;

Tibbitts, Jay ;

Holden, Scott N. ;

Sliwkowski, Mark X. ;

Phillips, Gail D. Lewis .

CLINICAL BREAST CANCER, 2011, 11 (05) :275-282

[10]

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

← 1 2 3 4 5 6 →